Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Acquired by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 32.5% in the third quarter, according to its most recent filing with the SEC. The fund owned 272,097 shares of the medical device company's stock after acquiring an additional 66,687 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned about 0.42% of Tandem Diabetes Care worth $11,540,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of TNDM. Assetmark Inc. bought a new position in Tandem Diabetes Care in the 3rd quarter valued at $29,000. ORG Wealth Partners LLC purchased a new position in Tandem Diabetes Care in the 3rd quarter worth about $30,000. ORG Partners LLC bought a new stake in Tandem Diabetes Care during the 2nd quarter valued at about $31,000. Waldron Private Wealth LLC bought a new position in Tandem Diabetes Care in the 3rd quarter worth about $50,000. Finally, Headlands Technologies LLC increased its holdings in Tandem Diabetes Care by 110.0% during the 2nd quarter. Headlands Technologies LLC now owns 2,060 shares of the medical device company's stock worth $83,000 after purchasing an additional 1,079 shares during the period.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on TNDM. Morgan Stanley reiterated an "equal weight" rating and issued a $45.00 target price on shares of Tandem Diabetes Care in a report on Monday, September 23rd. The Goldman Sachs Group started coverage on shares of Tandem Diabetes Care in a report on Friday, October 4th. They set a "neutral" rating and a $46.00 target price on the stock. Sanford C. Bernstein initiated coverage on shares of Tandem Diabetes Care in a report on Wednesday, November 6th. They issued an "outperform" rating and a $42.00 price target for the company. Canaccord Genuity Group assumed coverage on shares of Tandem Diabetes Care in a report on Thursday, August 8th. They set a "buy" rating and a $57.00 price objective on the stock. Finally, Piper Sandler reissued an "overweight" rating and set a $55.00 price target (up from $50.00) on shares of Tandem Diabetes Care in a research report on Friday, August 2nd. Five equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $54.25.

Insider Buying and Selling

In other Tandem Diabetes Care news, Director Kim D. Blickenstaff sold 10,000 shares of the company's stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $30.00, for a total transaction of $300,000.00. Following the completion of the transaction, the director now directly owns 195,190 shares in the company, valued at approximately $5,855,700. This represents a 4.87 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 2.20% of the stock is currently owned by insiders.

Tandem Diabetes Care Stock Performance

NASDAQ:TNDM traded up $0.07 during trading hours on Friday, reaching $30.81. The company had a trading volume of 1,227,984 shares, compared to its average volume of 1,606,265. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32. Tandem Diabetes Care, Inc. has a 1-year low of $18.45 and a 1-year high of $53.69. The business's 50 day moving average price is $36.42 and its 200-day moving average price is $41.35. The firm has a market cap of $2.02 billion, a PE ratio of -15.93 and a beta of 1.36.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The medical device company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.08. The firm had revenue of $243.97 million for the quarter, compared to the consensus estimate of $224.14 million. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The firm's quarterly revenue was up 31.4% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.38) earnings per share. Research analysts forecast that Tandem Diabetes Care, Inc. will post -1.73 EPS for the current year.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.